Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 2, Multicenter, Open-label, Randomized, Controlled Study of LX2006 Gene Therapy in Participants With Friedreich Ataxia Cardiomyopathy (SUNRISE-FA 2)

The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy…

Friedreich AtaxiaCardiomyopathy, Secondary

Estimated

~$10 – $8,750

Lexeo TherapeuticsNCT07721025